Clinical Trial Detail

NCT ID NCT02387125
Title A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Immune Design
Indications

myxoid liposarcoma

lung non-small cell carcinoma

melanoma

ovarian cancer

Advanced Solid Tumor

sarcoma

fallopian tube carcinoma

synovial sarcoma

Therapies

CMB305

Age Groups: adult

Additional content available in CKB BOOST